Hims & Hers stock jumps as Canaccord lifts target ahead of FDA review
Hims & Hers Health shares (HIMS) surged 9% on Wednesday after Canaccord Genuity raised its price target on the telehealth company, citing improving sales trends, momentum in its weight-loss business, and growing optimism around its peptide opportunity.Canaccord analyst Maria Ripps maintained a Buy…